Quality of life and economic impact of switching from established infliximab therapy to adalimumab in patients with rheumatoid arthritis

Trial Profile

Quality of life and economic impact of switching from established infliximab therapy to adalimumab in patients with rheumatoid arthritis

Completed
Phase of Trial: Phase III

Latest Information Update: 31 Oct 2009

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Oct 2009 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top